Effects of sodium phosphate and beetroot juice supplementation on repeated-sprint ability in females.

INTRODUCTION: Sodium phosphate (SP) and beetroot juice (BJ) supplementation was assessed on repeated-sprint ability (RSA). METHODS: Thirteen female team-sport participants completed four trials: (1) SP and BJ (SP + BJ), (2) SP and placebo (for BJ), (3) BJ and placebo (for SP) and (4) placebo (for SP + BJ), with ~21 days separating each trial. After each trial, participants performed a simulated team-game circuit (STGC) consisting of four 15 min quarters, with a 6 × 20-m repeated-sprint set performed at the start, half-time and end. RESULTS: Total sprint times were between 0.95-1.30 and 0.83-1.12 s faster for each RSA set and 3.25 and 3.12 s faster overall (~5% improvement) after SP compared with placebo and BJ, respectively (p = 0.02 for sets 1, 2 and overall; Cohen's effect size: d = -0.51 to -0.90 for all sets and overall). Additionally, total sprint times were 0.48 s faster after SP + BJ compared with placebo (set 2; p = 0.05, ~2% improvement). Furthermore, best sprints were 0.13-0.23 and 0.15-0.20 s faster (~6% improvement; p < 0.01) after SP compared with placebo and BJ, respectively, for all sets (d = -0.54 to -0.89). CONCLUSION: SP improved RSA in team-sport, female athletes when fresh (set 1) and during the later sets of a STGC (sets 2 and 3). Specifically, total and best sprint times were faster after SP compared with placebo and BJ.

Sodium phosphate supplementation and time trial performance in female cyclists.

This study investigated the effects of three doses of sodium phosphate (SP) supplementation on cycling 500 kJ (119.5 Kcal) time trial (TT) performance in female cyclists. Thirteen cyclists participated in a randomised, Latin-square design study where they completed four separate trials after ingesting either a placebo, or one of three different doses (25, 50 or 75 mg·kg(-1) fat free mass: FFM) of trisodium phosphate dodecahydrate which was split into four equal doses a day for six days. On the day after the loading phase, the TT was performed on a cycle ergometer. Serum phosphate blood samples were taken at rest both before and after each loading protocol, while a ~21 day washout period separated each loading phase. No significant differences in TT performance were observed between any of the supplementation protocols (p = 0.73) with average completion times for the 25, 50 or 75 mg·kg(-1) FFM being, 42:21 ± 07:53, 40:55 ± 07:33 and 40:38 ± 07:20 min respectively, and 40:39 ± 07:51 min for the placebo. Likewise, average and peak power output did not significantly differ between trials (p = 0.06 and p = 0.46, respectively). Consequently, 500 kJ cycling TT performance was not different in any of the supplementation protocols in female cyclists. Key PointsNo significant benefit of a 25, 50 or 75 mg·kg(-1) of FFM dose of sodium phosphate was found on 500 kJ (119.5 Kcal) TT cycle performance in female cyclists.Females of differing fitness levels responded similarly to sodium phosphate supplementation.Due to the possibility of individual responders to either the 50 or 75 mg·kg(-1) of FFM loading protocols, competitive cyclists should trial these doses prior to competition.

Sodium phosphate as an ergogenic aid.

Legal nutritional ergogenic aids can offer athletes an additional avenue to enhance their performance beyond what they can achieve through training. Consequently, the investigation of new nutritional ergogenic aids is constantly being undertaken. One emerging nutritional supplement that has shown some positive benefits for sporting performance is sodium phosphate. For ergogenic purposes, sodium phosphate is supplemented orally in capsule form, at a dose of 3-5 g/day for a period of between 3 and 6 days. A number of exercise performance-enhancing alterations have been reported to occur with sodium phosphate supplementation, which include an increased aerobic capacity, increased peak power output, increased anaerobic threshold and improved myocardial and cardiovascular responses to exercise. A range of mechanisms have been posited to account for these ergogenic effects. These include enhancements in 2,3-Diphosphoglycerate (2,3-DPG) concentrations, myocardial efficiency, buffering capacity and adenosine triphosphate/phosphocreatine synthesis. Whilst there is evidence to support the ergogenic benefits of sodium phosphate, many studies researching this substance differ in terms of the administered dose and dosing protocol, the washout period employed and the fitness level of the participants recruited. Additionally, the effect of gender has received very little attention in the literature. Therefore, the purpose of this review is to critically examine the use of sodium phosphate as an ergogenic aid, with a focus on identifying relevant further research.

A prospective randomised longitudinal MRI study of left ventricular adaptation to endurance and resistance exercise training in humans.

The principle that 'concentric' cardiac hypertrophy occurs in response to strength training, whilst 'eccentric' hypertrophy results from endurance exercise has been a fundamental tenet of exercise science. This notion is largely based on cross-sectional comparisons of athletes using echocardiography. In this study, young (27.4 ± 1.1 years) untrained subjects were randomly assigned to supervised, intensive, endurance (END, n = 10) or resistance (RES, n = 13) exercise and cardiac MRI scans and myocardial speckle tracking echocardiography were performed at baseline, after 6 months of training and after a subsequent 6 weeks of detraining. Aerobic fitness increased significantly in END (3.5 to 3.8 l min(-1), P < 0.05) but was unchanged in RES. Muscular strength significantly improved compared to baseline in both RES and END ( = 53.0 ± 1.1 versus 36.4 ± 4.5 kg, both P < 0.001) as did lean body mass (2.3 ± 0.4 kg, P < 0.001 versus 1.4 ± 0.6 kg P < 0.05). MRI derived left ventricular (LV) mass increased significantly following END (112.5 ± 7.3 to 121.8 ± 6.6 g, P < 0.01) but not RES, whilst training increased end-diastolic volume (LVEDV, END: +9.0 ± 5.0 versus RES +3.1 ± 3.6 ml, P = 0.05). Interventricular wall thickness significantly increased with training in END (1.06 ± 0.0 to 1.14 ± 0.06, P < 0.05) but not RES. Longitudinal strain and strain rates did not change following exercise training. Detraining reduced aerobic fitness, LV mass and wall thickness in END (P < 0.05), whereas LVEDV remained elevated. This study is the first to use MRI to compare LV adaptation in response to intensive supervised endurance and resistance training. Our findings provide some support for the 'Morganroth hypothesis', as it pertains to LV remodelling in response to endurance training, but cast some doubt over the proposal that remodelling occurs in response to resistance training.